Immunotherapy improves endometrial cancer outcomes

Rákkutatás · Endometrial cancer

Combining lenvatinib with pembrolizumab improves progression‑free and overall survival compared with chemotherapy in patients with advanced endometrial cancer.

This phase‑3 trial demonstrates that lenvatinib combined with the immune checkpoint inhibitor pembrolizumab provides a clinically meaningful benefit in survival outcomes for patients whose advanced endometrial cancer has progressed after platinum‑based chemotherapy, offering a new standard of care option in this setting.

Bizonyítékszint: Megerősített klinikai bizonyíték. Több vagy erősebb humán vizsgálat támogatja.

Eredeti forrás

Kapcsolódó jelek